CN102058854B - Chinese medicine for treating malignant lymphoma - Google Patents

Chinese medicine for treating malignant lymphoma Download PDF

Info

Publication number
CN102058854B
CN102058854B CN2011100212317A CN201110021231A CN102058854B CN 102058854 B CN102058854 B CN 102058854B CN 2011100212317 A CN2011100212317 A CN 2011100212317A CN 201110021231 A CN201110021231 A CN 201110021231A CN 102058854 B CN102058854 B CN 102058854B
Authority
CN
China
Prior art keywords
parts
chinese medicine
grams
radix
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2011100212317A
Other languages
Chinese (zh)
Other versions
CN102058854A (en
Inventor
许宗宽
谷高升
许博铨
Original Assignee
许宗宽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 许宗宽 filed Critical 许宗宽
Priority to CN2011100212317A priority Critical patent/CN102058854B/en
Publication of CN102058854A publication Critical patent/CN102058854A/en
Application granted granted Critical
Publication of CN102058854B publication Critical patent/CN102058854B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention relates to a Chinese medicine preparation for treating malignant lymphoma, which is an anticancer drug and has distinctive effects. The Chinese medicine preparation is prepared by the following Chinese medicine raw materials in parts by weight: 20-30 parts of ginseng, 1-2 parts of gamboge, 4-6 parts of toad skin, 10-20 parts of curcuma zedoary, 20-30 parts of prunella vulgaris, 10-20 parts of lithospermum, 10-20 parts of coix seeds and 20-30 parts of barbed skullcap herb. A preparation method of the Chinese medicine preparation comprises the following steps of: grinding 20-30 parts of ginseng, 1-2 parts of gamboge and 4-6 parts of toad skin into Chinese medicine powder, mixing the Chinese medicine powder with extracted concentrates of the five Chinese medicine raw materials of 10-20 parts of curcuma zedoary, 20-30 parts of prunella vulgaris, 10-20 parts of lithospermum, 10-20 parts of coix seeds and 20-30 parts of barbed skullcap in liquid phase to prepare pills. The pills have functions of strengthening and consolidating the body resistance, eliminating pathogenic factors, clearing heat and toxic materials, resolving hard lumps, promoting blood circulation and removing blood stasis, and improving human immunity, have the vigor to kill cancer cells and no obvious toxic effects for normal cells, and are used for treating malignant lymphoma.

Description

The Chinese medicine of treatment malignant lymphoma
Technical field
The present invention relates to a kind of Chinese medicine of treatment malignant lymphoma of anticarcinogen effect uniqueness, be used for the treatment of malignant lymphoma (non-Hodgkin), its function is a strengthening the body resistance, strengthening vital QI to eliminate pathogenic factors, heat-clearing and toxic substances removing, hard masses softening and resolving, blood circulation promoting and blood stasis dispelling, improve body immunity, have the vigor that kills and wounds cancerous cell, normal cell is not had the overt toxicity effect.
Background technology
Malignant lymphoma sickness rate height, early stage difficult discovery, the most of middle and advanced stage that belongs to of clinical findings, the limitation of operation and chemotherapy can't solve cancer infiltration and transfer; This tumor cure rate is difficult for the difficult problem of raising, although chemotherapy has the potential of whole body therapeutic, and outbreak repeatedly, chemotherapeutics makes patient be difficult to accept continuous treatment to the toxic and side effects of normal cell, tissue, and late result is undesirable.Therefore, China's tradition Chinese medicine has special advantages to treatment for cancer, and has formed strengthening the body resistance, strengthening vital QI to eliminate pathogenic factors, heat-clearing and toxic substances removing, hard masses softening and resolving, the theoretical system of blood circulation promoting and blood stasis dispelling and clinical verification.Using the Chinese medicine effective antitumor, is the problem that Chinese scholars, doctor family pay close attention to.
Summary of the invention
The objective of the invention is to overcome the defective that exists in the prior art and a kind of Chinese medicine that solves the treatment malignant lymphoma of the medication problem for the treatment of malignant lymphoma easily and effectively is provided.
The object of the present invention is achieved like this:
A kind of Chinese medicine for the treatment of malignant lymphoma is characterized in that: be prepared from by weight by following Chinese medicinal raw materials: Radix Ginseng 20-30 part, Resina garciniae 1-2 part, Cutis Bufonis 4-6 part, Rhizoma Curcumae 10-20 part, Spica Prunellae 20-30 part, Radix Arnebiae (Radix Lithospermi) 10-20 part, Semen Coicis 10-20 part, Herba Scutellariae Barbatae 20-30 part; Radix Ginseng 20-30 part, Resina garciniae 1-2 part, three kinds of raw material of Chinese medicine of Cutis Bufonis 4-6 part are ground into Chinese medicine powder, the extraction of this Chinese medicine powder and Rhizoma Curcumae 10-20 part, Spica Prunellae 20-30 part, Radix Arnebiae (Radix Lithospermi) 10-20 part, Semen Coicis 10-20 part, five kinds of raw material of Chinese medicine of Herba Scutellariae Barbatae 20-30 part is concentrated liquid-phase mixing, make pill and get final product.
The present invention has following good effect:
The present invention is according to Chinese medical theory, and cancer is many by feelings will, and internal injury is in melancholy anger; Daily life does not save, and six is defeated obstructed due to the overexertion, and wet is not all right, and blood coagulation is accumulate and wrapped up in and do not loose, and body fluid is puckery with fixed attention, work and not going, and amass.The above-mentioned cause of disease and cause qi depression to blood stasis accumulates pathogen to delay in the pyretic toxicity, gaze at hard; Visceral dysfunction, deficiency in both Qi and blood, meridian stasis resistance, the positive deficiency of vital energy, knot in the stasis of blood poison, the disease of forming stupid rock---cancer of a specified duration.Strengthening the body resistance, strengthening vital QI to eliminate pathogenic factors, heat-clearing and toxic substances removing, hard masses softening and resolving, blood circulation promoting and blood stasis dispelling are adopted in its treatment; It is then controlled: " disease caused by accumulations of pathogen should be treated with therapy of dispersion, hard masses should be resolved gradually."; To reach the treating both the principal and secondary aspects of a disease purpose.Adopt according to above-mentioned principle: Radix Ginseng, Resina garciniae, Cutis Bufonis, Chinese medicines such as Herba Scutellariae Barbatae are made and are got final product.The reasonable science of compatibility of the present invention, crude drug medicine source is abundant, and taking convenience has no side effect, good effect.Be easy to promote the use of.
By above-mentioned opinion, its rule of treatment: strengthening the body resistance, strengthening vital QI to eliminate pathogenic factors; And abide by " plain will discuss greatly " upright rule of treatment: " disease caused by accumulations of pathogen should be treated with therapy of dispersion, hard masses should be resolved gradually ... " to the most pure virginity; The side separates: Radix Ginseng: strengthening the body resistance; Rhizoma Curcumae, Spica Prunellae, Radix Arnebiae (Radix Lithospermi), Semen Coicis: eliminating stasis and resolving masses, heat-clearing and toxic substances removing, detumescence; Resina garciniae, Cutis Bufonis, Herba Scutellariae Barbatae: heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling, putrefaction removing and tissue regeneration promoting.Above-mentioned each formula combination together, mutually compatibility is given full play to curative effect of medication, that looses cuts it, suppresses interstitial laser photocoagulation, the newborn normal cell in generation is to have " putrefaction removing and tissue regeneration promoting ", " strengthening vital QI to eliminate pathogenic factors ", " eliminating evil and just do not hinder ", the effect of " strengthening the body resistance ".
One, trade name of the present invention is: join yellow ball.The curative effect judging standard of Chinese herbal treatment malignant tumor:
(1) cure: symptom, the complete obiteration of objective determination positive sign recovers certain work capacity, observes continuously more than 3 years and does not have the recidivist.
(2) clinical cure: the positive sign of symptom and objective determination disappears, and recovers certain work capacity;
1 grade: observing continuously more than 1 year does not have the recidivist;
2 grades: observe year no recidivist half a year to 1 continuously;
3 grades: observe 2 continuously---6 months no recidivists.
(3) produce effects: symptom disappears substantially, and focus is dwindled over half, and other objective determinations take an evident turn for the better.
1 grade: observe more than half a year no longer development person;
2 grades: observe 2---6 months development persons no longer.
(4) effective: symptom makes moderate progress, and focus is basicly stable, observes person more than 1 month;
(5) invalid: symptom and objective determination do not have improvement, or only have short-term to improve, and deterioration person rapidly.
Two, the criterion of therapeutical effect of solid tumor
(1) the visible pathological changes complete obiteration of measurable pathological changes: CR was above 1 month.The PR lump dwindles more than 50%, and the time was no less than for 4 weeks.
Measurement can adopt two footpaths to measure or single footpath is measured:
⒈ measures the single pathological changes of A. in two footpaths: tumor area (refer to two maximums of lump hang down the product in footpath) dwindles 〉=and 50%.
2. many pathological changes:
The maximum footpath sum of products of hanging down of a plurality of pathological changes reduces more than 50%.
The NC lump dwindles not as good as 50% or increases above 25%.
The one or more pathological changes of PD increase more than 25% or new pathological changes occurs.
(2) immeasurablel pathological changes
All symptoms of CR: at least 4 weeks of sign complete obiteration.
PR tumor size estimation reduces by 〉=50% at least 4 week.
The NC state of an illness does not have at least 4 weeks of significant change, and the tumor size estimation increases less than 25%, reduces less than 50%.
(3) bone shifts
Inspections such as CR X line and scanning, original at least 4 weeks of pathological changes complete obiteration.
The PR osteolytic lesion partly dwindles, and calcification or skeletonization osf density lower, at least 4 weeks.
The ND pathological changes does not have significant change, because osseous lesion often changes slowly, judges that NC at least should be after the 8th week of begin treatment.
The original focus of PD enlarges and/or new focus occurs.
Annotate: CR (Complete response) is alleviated fully; PR (partial response) part is alleviated; NC(no change) no change; PD (progressive disease) progress; Patient should not have new pathological changes appearance when being judged to PR, and any pathological changes gets nowhere.Fracture compression fracture and healing state thereof are as estimating the single index that bone shifts curative effect.
Three, clinical application research:
We's medicine is accepted late period more than 50 years old, the malignant lymphoma of chemotherapy repeatedly for medical treatment, with this preparation for treating totally 10 examples, all is the middle and advanced stage cancer, and clear and definite cytology is all arranged.Pathological diagnosis and can survey pathological changes, through 3---treatment in 6 months, clinical symptom disappearance, conscience, kidney, marrow function are normal, and life quality is higher.After treating three months,, do the treatment cross-reference by the CT check; Efficacy evaluation is evaluated by the WTO standard; Its result: inadequacy radiotherapy, chemotherapy.Its effective percentage is (CR+PR) 80%.
Table ⒈ (efficacy analysis)
? Alleviate fully Part is alleviated Stable Invalid Remarks
The example number 4 4 1 1 ?
Percentage rate 40 40 10 10 ?
The present invention inherits motherland's medicine and pharmacology theory, and in conjunction with the modern science and technology research method, clinical experimental research combines, meticulously compatibility; Repeatedly practise, develop the anticancer compound preparation of a kind of Chinese medicine at " malignant lymphoma ".Has strengthening the body resistance, strengthening vital QI to eliminate pathogenic factors, heat-clearing and toxic substances removing, hard masses softening and resolving, blood circulation promoting and blood stasis dispelling; And " eliminating evil and just do not hinder ", thereby improve " complete remission rate ", " the band cancer survival rate " of malignant lymphoma, obviously improve life quality, prolong life cycle, there is no obvious toxic and side effects.The present invention can be ground into Chinese medicine powder with Radix Ginseng 20-30 part, Resina garciniae 1-2 part, three kinds of raw material of Chinese medicine of Cutis Bufonis 4-6 part, with the extraction concentrated solution of Rhizoma Curcumae 10-20 part, Spica Prunellae 20-30 part, Radix Arnebiae (Radix Lithospermi) 10-20 part, Semen Coicis 10-20 part, five kinds of raw material of Chinese medicine of Herba Scutellariae Barbatae 20-30 part, make pill.Name of product is decided to be the yellow ball of ginseng.
Acute toxicity testing of the present invention is as follows: (mtd test)
Summary:
With Cmax (0.3g/ml), maximum administration volume (0.8ml/20g) kunming mice is irritated hello the yellow ball of ginseng successively, animal does not have death; To kunming mice twice administration in 8 hours at interval, animal does not have death with Cmax (0.3g/ml), maximum administration volume (0.8ml/20g).The result shows: this medicine maximum tolerated dose is greater than 24g/kg.
Test objective:
Observation is tried thing and is given the acute toxic reaction and the death condition that are produced behind the animal.
Be subjected to the reagent thing:
Title: join yellow ball
The unit of providing: Xu Zongkuan
Solvent: normal saline
Compound method: Radix Ginseng 20-30 part, Resina garciniae 1-2 part, three kinds of raw material of Chinese medicine of Cutis Bufonis 4-6 part are ground into Chinese medicine powder, the extraction of this Chinese medicine powder and Rhizoma Curcumae 10-20 part, Spica Prunellae 20-30 part, Radix Arnebiae (Radix Lithospermi) 10-20 part, Semen Coicis 10-20 part, five kinds of raw material of Chinese medicine of Herba Scutellariae Barbatae 20-30 part is concentrated liquid phase be mixed and made into pill, with pulverizer pill is broken into medicated powder, make it by 80 mesh sieves, with normal saline immersion, suspendible, be made into desired concn.
Animal:
Kunming mouse, laboratory animal institute of Chinese Academy of Medical Sciences breeding field provides.
The quality certification number: the moving word of doctor 01-3001 number
Test method:
One, trial test:
5 of kunming mices, body weight 19~21g, male.To join yellow ball and be suspended in the normal saline,
0.3g/ml the time medicinal liquid still can release through irritating the stomach pin, as Cmax, this concentration liquid with per 20 g Mus 0.8ml volumes, is once irritated stomach with this, observed for 1 week, the general situation of animal is good, does not have dead.
Two, Cmax, maximum administration volume single administration are observed:
The ⒈ experiment condition:
1. animal: Kunming mouse, 18~22g, each ten of male and female.
2. raise condition: room temperature: 23~25 ℃, relative humidity 50~60%, natural lighting.Feedstuff: full price battalion
Support pellet, provide by laboratory animal institute of medical courses in general institute breeding field.Drinking-water: city tap-water.The animal facility condition quality certification number: the moving word of doctor 01-2090 number.
3. medicine preparation: with the normal saline suspendible medicine of " joining yellow ball ", concentration is 0.3g/ml.
The ⒉ experimentation: with animal fasting 15 hours, every Mus was irritated with the 0.8ml/20g volume and feeds administration 1 time.(phase
When in per kilogram mice perfusion 12g).Observe after the administration, animal was stopped action in 2~3 hours, closed order, slight perpendicular hair, stopped into water, feed, and other is unusual but do not have.Movable as usual after 8 hours, feed, water inlet, defecation, all no abnormal discovery such as behavior.Observed 14 days none death of animal continuously.
Three, Cmax, maximum administration volume, secondary administration every day is observed
⒈ experiment condition: observe identical with Cmax, maximum administration volume single administration.
⒉ experimentation: animal fasting 15 hours.About at 9 o'clock in the morning, every Mus is irritated with the 0.8ml/20g volume
Hello " join yellow ball " suspension 1 time (being equivalent to per kilogram mice perfusion 12g), animal was stopped action in 2~3 hours after the administration, closed order, slight perpendicular hair, stopped into water, feed, found the individual animal laxativeness in 4~5 hours, other are unusual but do not have.About at 5 o'clock in afternoon, with same concentrations (0.3g/ml), equal volume (0.8ml/20g) rechallenge 1 time (being equivalent to per kilogram mice rechallenge 12 g), performance is similar with administration for the first time after the administration.All no abnormal discoveries such as animal activity, feed, water inlet, defecation, behavior after 15 hours.Observed 14 days continuously, animal does not have death.
Sum up:
To " join yellow ball " and feed for the filling of 18 ~ 22g Kunming mouse with Cmax, maximum administration volume, and observe 14 days continuously under 12g/kg dosage single administration situation, 20 animal subjects do not have the phenomena of mortality; Under 2 times on the one administration situations of 12g/kg dosage, 20 mices were observed 14 days continuously, did not also have dead the generation.
Conclusion:" join yellow ball " Kunming mouse is irritated hello administration maximum tolerated dose greater than 24g/kg.
Pharmacodynamic experiment of the present invention is as follows:
Summary:Adopt external (mtt assay), interior (animal transplanting tumor model) several different methods of body to carry out pharmacodynamic observation to joining yellow ball, the result shows: joining yellow pill powder has certain killing activity to non-Hodgkin lymphoma, and the cytotoxicity of normal l cell strain (Balb/3T3) is starkly lower than tumor cell line; Join yellow ball the mice non-Hodgkin lymphoma is had certain tumor-inhibiting action, and show dose-effect relationship preferably.
Test objective:Observe after the yellow ball administration of ginseng situation, this medicine is carried out pharmacodynamic action research tumor growth after the influence of tumor cell line and normal cell strain survival and the tumor animal medication.
Be subjected to the reagent thing:Title: join yellow ball.The unit of providing: by wide the providing of Zhengzhou, Henan Province Xu Zong.Solvent: normal saline.Compound method: Radix Ginseng 20-30 part, Resina garciniae 1-2 part, three kinds of raw material of Chinese medicine of Cutis Bufonis 4-6 part are ground into Chinese medicine powder, the extraction of this Chinese medicine powder and Rhizoma Curcumae 10-20 part, Spica Prunellae 20-30 part, Radix Arnebiae (Radix Lithospermi) 10-20 part, Semen Coicis 10-20 part, five kinds of raw material of Chinese medicine of Herba Scutellariae Barbatae 20-30 part is concentrated liquid phase be mixed and made into pill, with pulverizer pill is broken into medicated powder, make it by 80 mesh sieves, with normal saline immersion, suspendible, be mixed with desired concn.
Other medicines (positive control drug):
⒈ injection harringtonine, the Beijing XieHe medicine Factory produces;
The ⒉ Cyclophosphamide for injection, Hualian Pharmaceutical Co., Ltd., Shanghai produces.
Animal:
Kunming mouse is provided by laboratory animal institute of Chinese Academy of Medical Sciences breeding field, the quality certification number: the moving word of doctor 01-3001 number.
⒉ ICR mice is provided by laboratory animal institute of Chinese Academy of Medical Sciences breeding field, the quality certification number: the moving word of doctor 01-3007 number.
⒊ 615 mices are provided by laboratory animal institute of Chinese Academy of Medical Sciences breeding field,
Cell strain:
External: non-Hodgkin lymphoma cell strain, normal mouse fibroblast strain (Balb/3T3), by the preservation of going down to posterity of this laboratory.
One, the yellow ball of ginseng is to the research of the lethal effect of non-Hodgkin lymphoma
<experimental technique 〉
Cell culture:Cell culture in containing the RPMI1640 culture medium of 10% calf serum, is included penicillin 100U/ml, streptomycin 100ug/ml, in 37 ℃, the cultivation of going down to posterity in the 5%CO2 incubator.
The medicine preparation:Harringtonine, white powder, consonance pharmacy field produces, and uses anhydrous alcohol solution, dilutes with RPMI1640 during experiment, and final concentration is 0.001,0.005,0.01,0.05,0.1 ug/ml; Soak with the DMSO dissolving when joining the preparation of yellow ball, get supernatant, dilute with RPMI1640 during experiment, final concentration is 1,10,20,50,100 ug/ml.
Experiment:With the adherent tumor cell of 0.3% pancreatin, 0.6 ml digestion, with the RPMI1640 culture fluid preparation cell suspension that contains 10% calf serum, concentration is 1 * 104/ml.Every hole inoculation 100ul(contains 1000 tumor cells in 96 well culture plates), cultivated 24 hours for 37 ℃.The administration group adds the RPMI1640 culture medium that contains the variable concentrations medicine, and every hole 100 ul establish 5 dosage groups.Establish three parallel holes for every group.Matched group adds the RPMI1640 culture medium that contains the equal-volume solvent.With the positive contrast medicine of harringtonine.Put 30 ℃, cultivate after 4 days in the 5%CO2 incubator and discard culture fluid, every hole adds 200 ul 0.2%MTT solution (RPMI1640 preparation).37 ℃ are incubated 4 hours, supernatant discarded, and every hole adds DMSO150 ul dissolving Formazan granule, behind the gentle agitation, with MR700 type microplate reader, measures optical density value under reference wavelength 450nm, detection wavelength 570 nm conditions.
The result calculates:
The tumor cell of handling with solvent control is a matched group, ask medicine to the inhibition inhibition rate of tumor cell of tumor cell=
The average OD value of the matched group-average OD value of administration group
The average OD value of matched group * 100%
Can obtain dosage reflection curve with the variable concentrations of medicine and the suppression ratio mapping of pair cell, therefrom obtain the half-inhibition concentration of medicine.
Criterion:<30 ug/ml, then think has killing activity external to tumor cell to the IC50 of plant crude extract.
<experimental result 〉See Table 1.
Suppression ratio according to different pharmaceutical concentration and pair cell carries out computing, and three batches of experiments draw the yellow ball of ginseng different Xi Bao Zhu Tinkling IC50 are respectively:
HCT-8 cell: 15.15 ug/ml, 13.93 ug/ml, 16.86 ug/ml
X±SD:15.31±1.47?ug/ml
MGC80-3 cell: 15.61 ug/ml, 16.13 ug/ml, 16.04 ug/ml
X±SD:15.93±0.28ug/ml
A549 cell: 18.97 ug/ml, 18.50 ug/ml, 18.77 ug/ml
X±SD:18.75±0.24ug/ml
MCF-7 cell: 8.49 ug/ml, 10.03 ug/ml, 9.89 ug/ml
X±SD:9.47±0.85ug/ml
The Balb/3T3 cell:〉50 ug/ml, 50 ug/ml, 50 ug/ml
The result shows that the yellow ball of ginseng has certain killing activity to non-Hodgkin lymphoma, and is wherein the most responsive with breast carcinoma, and the cytotoxicity of normal fibroblast strain Balb/3T3 is starkly lower than above-mentioned four kinds of tumor cell lines.
Table 1-1 joins the lethal effect of yellow ball to human cancer cell
First
The cell strain harringtonine is joined yellow ball
────────── ─────────
Administration concentration suppression ratio IC50 administration concentration suppression ratio IC50
(ug/ml)(%)?(ug/ml)(ug/ml)?(%)(ug/ml)
HCT-8 0.001 3 0.046 1 8 15.15
(people 0.005 13 10 12
Colon 0.01 15 20 77
Cancer is thin by 0.05 54 50 87
Born of the same parents) 0.1 71 100 90
MGC80-3 0.001 0 0.027 1 0 15.61
(people pernicious 0.005 11 10 13
Lymphoma 0.01 34 20 79
Cell) 0.05 71 50 80
0.1 80 100 81
A549 0.001 5 0.032 1 3 18.97
(people 0.005 33 10 15
Pulmonary carcinoma 0.01 45 20 54
Cell) 0.05 63 50 60
0.1 67 100 67
MCF-7 0.001 16 0.004 1 15 8.49
(people 0.005 69 10 57
Mammary gland 0.01 75 20 65
Cancer is thin by 0.05 76 50 80
Born of the same parents) 0.1 80 100 85
Balb/3T3 0.001 4 〉0.1 1 8 〉50
(mice 0.005 16 10 23
Normal one-tenth 0.01 22 20 43
Fiber 0.05 39 50 44
Cell) 0.1 42 100 49
Table 1-2 joins the lethal effect of yellow ball to human cancer cell
Second batch
The cell strain harringtonine is joined yellow ball
────────── ─────────
Administration concentration suppression ratio IC50 administration concentration suppression ratio IC50
(ug/ml)(%)?(ug/ml)(ug/ml)?(%)(ug/ml)
HCT-8 0.001 2 0.058 1 8 13.93
(people 0.005 15 10 16
Colon 0.01 18 20 80
Cancer is thin by 0.05 52 50 88
Born of the same parents) 0.1 68 100 90
MGC80-3 0.001 0 0.047 1 0 16.13
(people 0.005 9 10 5
Pernicious 0.01 30 20 80
Lymphatic cancer 0.05 75 50 81
Cell) 0.1 81 100 82
A549 0.001 5 0.048 1 2 18.50
(people 0.005 30 10 13
Pulmonary carcinoma 0.01 43 20 56
Cell) 0.05 60 50 60
0.1 71 100 70
MCF-7 0.001 12 0.006 1 11 10.03
(people 0.005 58 10 54
Mammary gland 0.01 70 20 62
Cancer is thin by 0.05 79 50 74
Born of the same parents) 0.1 83 100 83
Balb/3T3 0.001 3 〉0.1 1 14 〉50
(mice 0.005 11 10 21
Normal one-tenth 0.01 20 20 43
Fiber 0.05 36 50 45
Cell) 0.1 45 100 48
Table 1-3 joins the lethal effect of yellow ball to human cancer cell
The 3rd batch
The cell strain harringtonine is joined yellow ball
────────── ─────────
Administration concentration suppression ratio IC50 administration concentration suppression ratio IC50
(ug/ml)(%)?(ug/ml)(ug/ml)?(%)(ug/ml)
HCT-8 0.001 5 0.058 1 13 16.86
(people 0.005 18 10 15
Colon 0.01 20 20 76
Cancer is thin by 0.05 58 50 87
Born of the same parents) 0.1 70 100 89
MGC80-3 0.001 0 0.049 1 0 16.04
(people 0.005 9 10 10
Pernicious 0.01 30 20 77
Lymphatic cancer 0.05 65 50 82
Cell) 0.1 82 100 83
A549 0.001 3 0.048 1 5 18.77
(people 0.005 28 10 17
Pulmonary carcinoma 0.01 43 20 54
Cell) 0.05 60 50 65
0.1 74 100 70
MCF-7 0.001 18 0.006 1 11 9.89
(people 0.005 59 10 56
Mammary gland 0.01 70 20 61
Cancer is thin by 0.05 80 50 81
Born of the same parents) 0.1 85 100 85
Balb/3T3 0.001 8 〉0.1 1 10 〉50
(mice 0.005 12 10 20
Normal one-tenth 0.01 24 20 42
Fiber 0.05 36 50 44
Cell) 0.1 48 100 49
Two, the yellow ball of ginseng is observed the transplanted tumor effect
⒈ joins yellow ball to the H22 tumor-inhibiting action
<experimental technique 〉Select the ICR mice for use, 18 ~ 22g, male and female dual-purpose (every batch of same sex of experiment), the tumor animal cervical vertebra dislocation that inoculation is back 8 days is put to death.Aseptic condition takes out ascites down, with normal saline 1:2 dilution, gives every Mus axillary fossa subcutaneous vaccination tumor liquid 0.2ml.
Next day after the inoculation, animal is divided into groups immediately, weighs, join yellow ball and establish three dosage groups, establish positive control (cyclophosphamide) and negative control group simultaneously, every group of 10 animals.By 1.2,2.4,4.8g/kg three dosage irritate stomach with equal-volume (0.8ml) variable concentrations to animal, once a day, successive administration 8 days.Positive controls is given animal intraperitoneal injection of cyclophosphamide 1 time with 100mg/kg dosage in inoculation next day.After the last administration 24 hours, animal was put to death in the cervical vertebra dislocation, weighed respectively, tumor is heavy, calculates tumor control rate, the row therapeutic evaluation.And each is organized result carry out statistical procedures.The curative effect science judgement schematics:
Tumor control rate (%)=
It is heavy that average tumor is organized in the average tumor weight-treatment of matched group
The average tumor of matched group heavy * 100
This experiment repeats secondary.
<experimental result 〉Three batches the results are shown in Table 2.
The result shows: join yellow ball with 1.2,2.4,4.8g/kg dosage gastric infusion, can obviously suppress the growth of mice H22 solid tumor, show dose-dependence preferably.
⒉ joins yellow ball to murine sarcoma S180 tumor-inhibiting action
<experimental technique 〉Select the ICR mice for use, 18 ~ 22g, male and female dual-purpose (every batch of same sex of experiment), the tumor animal cervical vertebra dislocation that inoculation is back 8 days is put to death.Aseptic condition takes out ascites down, with normal saline 1:2 dilution, gives every Mus axillary fossa subcutaneous vaccination tumor liquid 0.2ml.
Next day after the inoculation, animal is divided into groups immediately, weighs, join yellow ball and establish three dosage groups, establish positive control (cyclophosphamide) and negative control group simultaneously, every group of 10 animals.By 1.2,2.4,4.8g/kg three dosage irritate stomach with equal-volume (0.8ml) variable concentrations to animal, once a day, successive administration 8 days.Positive controls is given animal intraperitoneal injection of cyclophosphamide 1 time with 100mg/kg dosage in inoculation next day.After the last administration 24 hours, animal was put to death in the cervical vertebra dislocation, weighed respectively, tumor is heavy, calculates tumor control rate, the row therapeutic evaluation.And each is organized result carry out statistical procedures.The curative effect science judgement schematics:
Tumor control rate (%)=
It is heavy that average tumor is organized in the average tumor weight-treatment of matched group
The average tumor of matched group heavy * 100
This experiment repeats secondary.
<experimental result 〉Three batches the results are shown in Table 3.
The result shows: join yellow ball with 1.2,2.4,4.8g/kg dosage gastric infusion, can obviously suppress the growth of mice H22 solid tumor, show dose-dependence preferably.
⒊ joins yellow ball powder to mice non-Hodgkin lymphoma tumor-inhibiting action
<experimental technique 〉Select the ICR mice for use, 18 ~ 22g, male and female dual-purpose (every batch of same sex of experiment), the tumor animal cervical vertebra dislocation that inoculation is back 8 days is put to death.Aseptic condition takes out ascites down, with normal saline 1:2 dilution, gives every Mus axillary fossa subcutaneous vaccination tumor liquid 0.2ml.
Next day after the inoculation, animal is divided into groups immediately, weighs, join yellow ball and establish three dosage groups, establish positive control (cyclophosphamide) and negative control group simultaneously, every group of 10 animals.By 1.2,2.4,4.8g/kg three dosage irritate stomach with equal-volume (0.8ml) variable concentrations to animal, once a day, successive administration 8 days.Positive controls is given animal intraperitoneal injection of cyclophosphamide 1 time with 100mg/kg dosage in inoculation next day.After the last administration 24 hours, animal was put to death in the cervical vertebra dislocation, weighed respectively, tumor is heavy, calculates tumor control rate, the row therapeutic evaluation.And each is organized result carry out statistical procedures.The curative effect science judgement schematics:
Tumor control rate (%)=
It is heavy that average tumor is organized in the average tumor weight-treatment of matched group
The average tumor of matched group heavy * 100
This experiment repeats secondary.
<experimental result 〉
Three batches the results are shown in Table 4.The result shows: join yellow ball with 1.2,2.4,4.8g/kg dosage gastric infusion, can obviously suppress the growth of mice H22 solid tumor, show dose-dependence preferably.
Table ⒉ joins the inhibitory action of yellow ball to rat liver cancer H22
Experimenter: pay and recruit sister-in-law Li Yan
The heavy suppression ratio of batch drug dose number of animals (only) body weight (g) tumor
┄┄┄┄┄┄┄┄┄┄┄┄┄┄┄┄
(mg/kg) before the administration after the administration before the administration after the administration (g)
Matched group 10 10 19.4 ± 2.36 25.1 ± 2.16 1.72 ± 0.421
Ring phosphinylidyne 100 * 1 10 10 18.2 ± 1.90 23.5 ± 2.94 0.23 ± 0.0949 86.7
Join yellow ball 1200 * 8 10 10 20.0 ± 1.20 24.6 ± 3.83 1.31 ± 0.557 23.8
2400×8 10 10 19.7±1.29 21.9±3.99 1.03±0.452 40.1
4800×8 10 8 19.6±1.36 19.3±2.12 0.79±0.280 54.1
Matched group 10 10 19.3 ± 1.64 22.3 ± 1.95 1.54 ± 0.284
Cyclophosphamide 100 * 1 10 10 19.7 ± 1.56 23.8 ± 2.04 0.20 ± 0.0943 87.0
Join yellow ball 1200 * 8 10 10 18.2 ± 4.21 23.7 ± 1.92 1.23 ± 0.501 20.1
2400×8 10 10 20.0±1.32 22.4±8.03 0.95±0.344 38.3
4800×8 10 8 19.0±1.97 19.4±2.40 0.71±0.259 53.9
Matched group 10 10 18.1 ± 1.38 23.0 ± 4.03 1.53 ± 0.253
Cyclophosphamide 100 * 1 10 10 22.6 ± 2.19 20.4 ± 6.86 0.16 ± 0.181 89.5
Join yellow ball 1200 * 8 10 10 16.7 ± 0.82 18.3 ± 11.7 1.21 ± 0.384 20.9
2400×8 10 10 17.5±0.85 21.0±2.04 1.01±0.208 34.0
4800×8 10 10 18.0±1.56 17.1±4.09 0.76±0.201 50.3
P 0.05 with the normal control group relatively
Table ⒊ joins the inhibitory action of yellow ball to murine sarcoma S180
The heavy suppression ratio of batch drug dose number of animals (only) body weight (g) tumor
┄┄┄┄┄┄┄┄┄┄┄┄┄┄┄┄
(mg/kg) before the administration after the administration before the administration after the administration (g)
Matched group 10 10 20.9 ± 1.85 27.6 ± 2.84 2.89 ± 1.336
Cyclophosphamide 100 * 1 10 10 18.6 ± 4.25 26.6 ± 2.92 0.41 ± 0.256 85.8
Join yellow ball 1200 * 8 10 10 20.5 ± 2.03 28.1 ± 3.65 1.96 ± 0.660 32.2
2400×8 10 9 20.6±1.70 26.9±3.51 1.33±0.287 54.0
4800×8 10 9 19.9±1.79 22.9±4.22 0.69±0.247 76.1
Matched group 10 10 18.3 ± 1.86 24.5 ± 0.97 2.46 ± 0.530
Cyclophosphamide 100 * 1 10 10 19.1 ± 3.12 21.7 ± 1.60 0.45 ± 0.201 81.7
Join yellow ball 1200 * 8 10 10 19.1 ± 2.40 23.6 ± 2.41 1.98 ± 0.702 19.5
2400×8 10 10 19.5±1.52 23.9±2.18 1.32±0.319 46.3
4800×8 10 10 18.4±2.34 20.5±3.27 0.79±0.393 67.9
Matched group 10 10 18.4 ± 1.97 25.7 ± 2.83 2.57 ± 0.581
Cyclophosphamide 100 * 1 10 9 19.2 ± 2.03 23.5 ± 3.05 0.49 ± 0.262 80.9
Join yellow ball 1200 * 8 10 9 18.6 ± 1.82 25.2 ± 1.48 1.92 ± 0.452 25.3
2400×8 10 10 19.4±1.79 23.1±2.56 1.44±0.462 44.0
4800×8 10 10 17.3±1.60 19.9±3.07 0.92±0.447 64.2
P 0.05 with the normal control group relatively
Table ⒋ joins the inhibitory action of yellow ball to the mice non-Hodgkin lymphoma
The heavy suppression ratio of batch drug dose number of animals (only) body weight (g) tumor
┄┄┄┄┄┄┄┄┄┄┄┄┄┄┄┄
(mg/kg) before the administration after the administration before the administration after the administration (g)
Matched group 10 10 19.8 ± 1.32 19.0 ± 2.03 2.08 ± 0.571
Cyclophosphamide 100 * 1 10 10 18.8 ± 1.27 19.5 ± 2.51 1.13 ± 0.221 45.7
Join yellow ball 1200 * 8 10 10 19.7 ± 3.02 20.7 ± 1.34 1.75 ± 0.552 15.9
2400×8 10 10 19.3±1.65 16.8±2.34 1.39±0.540 33.2
4800×8 10 8 19.2±0.949 17.8±1.58 0.94±0.441 54.8
Matched group 10 10 20.3 ± 2.20 19.2 ± 2.97 1.72 ± 0.379
Cyclophosphamide 100 * 1 10 9 19.5 ± 1.70 16.6 ± 1.59 1.02 ± 0.199 40.7
Join yellow ball 1200 * 8 10 9 18.9 ± 2.24 19.7 ± 3.16 1.44 ± 0.378 16.3
2400×8 10 8 19.8±2.10 22.4±3.20 1.20±0.484 30.2
4800×8 10 10 18.7±1.77 17.5±2.58 0.80±0.237 53.5
Matched group 10 10 20.2 ± 2.20 20.2 ± 3.09 1.62 ± 0.335
Cyclophosphamide 100 * 1 10 9 19.5 ± 1.47 19.7 ± 4.59 0.86 ± 0.188 46.9
Join yellow ball 1200 * 8 10 10 19.9 ± 1.53 19.5 ± 3.41 1.23 ± 0.473 14.1
2400×8 10 10 19.3±1.70 20.2±2.92 1.03±0.283 36.4
4800×8 10 9 19.5±1.91 18.6±2.87 0.80±0.156 50.6
P 0.05 with the normal control group relatively
Conclusion:Adopting the yellow ball of the wide ginseng that provides of Zhengzhou, Henan Province Xu Zong to carry out mtt assay at non-Hodgkin lymphoma cell strain, human lung adenocarcinoma cell line (A549), human colon cancer cell strain (HCT-8), human breast cancer cell strain (MCF-7), normal mouse fibroblast strain (Balb/3T3) cell strain detects, the result shows: joining yellow ball all has certain killing activity to used tumor cell line, and normal cell killing effect is obviously weakened.Join yellow ball and all show tumor-inhibiting action preferably at murine sarcoma S180, rat liver cancer H22, mice non-Hodgkin lymphoma animal transplanting tumor model, tumour inhibiting rate and dosage positive correlation, repeatability is better.
The specific embodiment:
Embodiment 1: be prepared from by weight by following Chinese medicinal raw materials: Radix Ginseng 30 grams, Resina garciniae 1 gram, Cutis Bufonis 4 grams, Rhizoma Curcumae 10 grams, Spica Prunellae 20 grams, Radix Arnebiae (Radix Lithospermi) 10 grams, Semen Coicis 10 grams, Herba Scutellariae Barbatae 20 grams; Radix Ginseng, Resina garciniae, three kinds of raw material of Chinese medicine of Cutis Bufonis are ground into Chinese medicine powder, the extraction of this Chinese medicine powder and Rhizoma Curcumae, Spica Prunellae, Radix Arnebiae (Radix Lithospermi), Semen Coicis, five kinds of raw material of Chinese medicine of Herba Scutellariae Barbatae is concentrated liquid-phase mixing, make pill and get final product.
Embodiment 2: be prepared from by weight by following Chinese medicinal raw materials: Radix Ginseng 20 grams, Resina garciniae 2 grams, Cutis Bufonis 4 grams, Rhizoma Curcumae 10 grams, Spica Prunellae 20 grams, Radix Arnebiae (Radix Lithospermi) 10 grams, Semen Coicis 10 grams, Herba Scutellariae Barbatae 20 grams; Radix Ginseng, Resina garciniae, three kinds of raw material of Chinese medicine of Cutis Bufonis are ground into Chinese medicine powder, the extraction of this Chinese medicine powder and Rhizoma Curcumae, Spica Prunellae, Radix Arnebiae (Radix Lithospermi), Semen Coicis, five kinds of raw material of Chinese medicine of Herba Scutellariae Barbatae is concentrated liquid-phase mixing, make pill and get final product.
Embodiment 3: be prepared from by weight by following Chinese medicinal raw materials: Radix Ginseng 20 grams, Resina garciniae 1 gram, Cutis Bufonis 6 grams, Rhizoma Curcumae 10 grams, Spica Prunellae 20 grams, Radix Arnebiae (Radix Lithospermi) 10 grams, Semen Coicis 10 grams, Herba Scutellariae Barbatae 20 grams; Radix Ginseng, Resina garciniae, three kinds of raw material of Chinese medicine of Cutis Bufonis are ground into Chinese medicine powder, the extraction of this Chinese medicine powder and Rhizoma Curcumae, Spica Prunellae, Radix Arnebiae (Radix Lithospermi), Semen Coicis, five kinds of raw material of Chinese medicine of Herba Scutellariae Barbatae is concentrated liquid-phase mixing, make pill and get final product.
Embodiment 4: be prepared from by weight by following Chinese medicinal raw materials: Radix Ginseng 20 grams, Resina garciniae 1 gram, Cutis Bufonis 4 grams, Rhizoma Curcumae 20 grams, Spica Prunellae 20 grams, Radix Arnebiae (Radix Lithospermi) 10 grams, Semen Coicis 10 grams, Herba Scutellariae Barbatae 20 grams; Radix Ginseng, Resina garciniae, three kinds of raw material of Chinese medicine of Cutis Bufonis are ground into Chinese medicine powder, the extraction of this Chinese medicine powder and Rhizoma Curcumae, Spica Prunellae, Radix Arnebiae (Radix Lithospermi), Semen Coicis, five kinds of raw material of Chinese medicine of Herba Scutellariae Barbatae is concentrated liquid-phase mixing, make pill and get final product.
Embodiment 5: be prepared from by weight by following Chinese medicinal raw materials: Radix Ginseng 20 grams, Resina garciniae 1 gram, Cutis Bufonis 4 grams, Rhizoma Curcumae 10 grams, Spica Prunellae 30 grams, Radix Arnebiae (Radix Lithospermi) 10 grams, Semen Coicis 10 grams, Herba Scutellariae Barbatae 20 grams; Radix Ginseng, Resina garciniae, three kinds of raw material of Chinese medicine of Cutis Bufonis are ground into Chinese medicine powder, the extraction of this Chinese medicine powder and Rhizoma Curcumae, Spica Prunellae, Radix Arnebiae (Radix Lithospermi), Semen Coicis, five kinds of raw material of Chinese medicine of Herba Scutellariae Barbatae is concentrated liquid-phase mixing, make pill and get final product.
Embodiment 6: be prepared from by weight by following Chinese medicinal raw materials: Radix Ginseng 20 grams, Resina garciniae 1 gram, Cutis Bufonis 4 grams, Rhizoma Curcumae 10 grams, Spica Prunellae 20 grams, Radix Arnebiae (Radix Lithospermi) 20 grams, Semen Coicis 10 grams, Herba Scutellariae Barbatae 20 grams; Radix Ginseng, Resina garciniae, three kinds of raw material of Chinese medicine of Cutis Bufonis are ground into Chinese medicine powder, the extraction of this Chinese medicine powder and Rhizoma Curcumae, Spica Prunellae, Radix Arnebiae (Radix Lithospermi), Semen Coicis, five kinds of raw material of Chinese medicine of Herba Scutellariae Barbatae is concentrated liquid-phase mixing, make pill and get final product.
Embodiment 7: be prepared from by weight by following Chinese medicinal raw materials: Radix Ginseng 20 grams, Resina garciniae 1 gram, Cutis Bufonis 4 grams, Rhizoma Curcumae 10 grams, Spica Prunellae 20 grams, Radix Arnebiae (Radix Lithospermi) 10 grams, Semen Coicis 20 grams, Herba Scutellariae Barbatae 20 grams; Radix Ginseng, Resina garciniae, three kinds of raw material of Chinese medicine of Cutis Bufonis are ground into Chinese medicine powder, the extraction of this Chinese medicine powder and Rhizoma Curcumae, Spica Prunellae, Radix Arnebiae (Radix Lithospermi), Semen Coicis, five kinds of raw material of Chinese medicine of Herba Scutellariae Barbatae is concentrated liquid-phase mixing, make pill and get final product.
Embodiment 8: be prepared from by weight by following Chinese medicinal raw materials: Radix Ginseng 20 grams, Resina garciniae 1 gram, Cutis Bufonis 4 grams, Rhizoma Curcumae 10 grams, Spica Prunellae 20 grams, Radix Arnebiae (Radix Lithospermi) 10 grams, Semen Coicis 10 grams, Herba Scutellariae Barbatae 30 grams; Radix Ginseng, Resina garciniae, three kinds of raw material of Chinese medicine of Cutis Bufonis are ground into Chinese medicine powder, the extraction of this Chinese medicine powder and Rhizoma Curcumae, Spica Prunellae, Radix Arnebiae (Radix Lithospermi), Semen Coicis, five kinds of raw material of Chinese medicine of Herba Scutellariae Barbatae is concentrated liquid-phase mixing, make pill and get final product.
Embodiment 9: be prepared from by weight by following Chinese medicinal raw materials: Radix Ginseng 20 grams, Resina garciniae 1 gram, Cutis Bufonis 4 grams, Rhizoma Curcumae 10 grams, Spica Prunellae 20 grams, Radix Arnebiae (Radix Lithospermi) 10 grams, Semen Coicis 10 grams, Herba Scutellariae Barbatae 20 grams; Radix Ginseng, Resina garciniae, three kinds of raw material of Chinese medicine of Cutis Bufonis are ground into Chinese medicine powder, the extraction of this Chinese medicine powder and Rhizoma Curcumae, Spica Prunellae, Radix Arnebiae (Radix Lithospermi), Semen Coicis, five kinds of raw material of Chinese medicine of Herba Scutellariae Barbatae is concentrated liquid-phase mixing, make pill and get final product.
Embodiment 10: be prepared from by weight by following Chinese medicinal raw materials: Radix Ginseng 30 grams, Resina garciniae 2 grams, Cutis Bufonis 6 grams, Rhizoma Curcumae 20 grams, Spica Prunellae 30 grams, Radix Arnebiae (Radix Lithospermi) 20 grams, Semen Coicis 20 grams, Herba Scutellariae Barbatae 30 grams; Radix Ginseng, Resina garciniae, three kinds of raw material of Chinese medicine of Cutis Bufonis are ground into Chinese medicine powder, the extraction of this Chinese medicine powder and Rhizoma Curcumae, Spica Prunellae, Radix Arnebiae (Radix Lithospermi), Semen Coicis, five kinds of raw material of Chinese medicine of Herba Scutellariae Barbatae is concentrated liquid-phase mixing, make pill and get final product.
Embodiment 11: be prepared from by weight by following Chinese medicinal raw materials: Radix Ginseng 15 grams, Resina garciniae 1.5 grams, Cutis Bufonis 5 grams, Rhizoma Curcumae 15 grams, Spica Prunellae 25 grams, Radix Arnebiae (Radix Lithospermi) 15 grams, Semen Coicis 15 grams, Herba Scutellariae Barbatae 25 grams; Radix Ginseng, Resina garciniae, three kinds of raw material of Chinese medicine of Cutis Bufonis are ground into Chinese medicine powder, the extraction of this Chinese medicine powder and Rhizoma Curcumae, Spica Prunellae, Radix Arnebiae (Radix Lithospermi), Semen Coicis, five kinds of raw material of Chinese medicine of Herba Scutellariae Barbatae is concentrated liquid-phase mixing, make pill and get final product.

Claims (1)

1. a Chinese medicine for the treatment of malignant lymphoma is characterized in that: be prepared from by weight by following Chinese medicinal raw materials: Radix Ginseng 20-30 part, Resina garciniae 1-2 part, Cutis Bufonis 4-6 part, Rhizoma Curcumae 10-20 part, Spica Prunellae 20-30 part, Radix Arnebiae (Radix Lithospermi) 10-20 part, Semen Coicis 10-20 part, Herba Scutellariae Barbatae 20-30 part; Radix Ginseng 20-30 part, Resina garciniae 1-2 part, three kinds of raw material of Chinese medicine of Cutis Bufonis 4-6 part are ground into Chinese medicine powder, the extraction of this Chinese medicine powder and Rhizoma Curcumae 10-20 part, Spica Prunellae 20-30 part, Radix Arnebiae (Radix Lithospermi) 10-20 part, Semen Coicis 10-20 part, five kinds of raw material of Chinese medicine of Herba Scutellariae Barbatae 20-30 part is concentrated liquid-phase mixing, make pill and get final product.
CN2011100212317A 2011-01-19 2011-01-19 Chinese medicine for treating malignant lymphoma Active CN102058854B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2011100212317A CN102058854B (en) 2011-01-19 2011-01-19 Chinese medicine for treating malignant lymphoma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011100212317A CN102058854B (en) 2011-01-19 2011-01-19 Chinese medicine for treating malignant lymphoma

Publications (2)

Publication Number Publication Date
CN102058854A CN102058854A (en) 2011-05-18
CN102058854B true CN102058854B (en) 2011-11-09

Family

ID=43994479

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011100212317A Active CN102058854B (en) 2011-01-19 2011-01-19 Chinese medicine for treating malignant lymphoma

Country Status (1)

Country Link
CN (1) CN102058854B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103705897B (en) * 2014-01-03 2016-04-13 陈延玲 A kind of cancer relieves the pain plaster
CN104042669A (en) * 2014-07-14 2014-09-17 许博铨 Traditional Chinese medicine for treating liver cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101249245A (en) * 2006-12-26 2008-08-27 徐婧琳 Medicament for curing esophagus cancer and cardiac cancer
CN101293060A (en) * 2008-06-11 2008-10-29 许宗宽 Traditional Chinese medicine for treating cytology specification adenocarcinoma
CN101564464A (en) * 2009-06-01 2009-10-28 朱志真 Chinese medicament for adjusting organism immunity of tumor patients

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101249245A (en) * 2006-12-26 2008-08-27 徐婧琳 Medicament for curing esophagus cancer and cardiac cancer
CN101293060A (en) * 2008-06-11 2008-10-29 许宗宽 Traditional Chinese medicine for treating cytology specification adenocarcinoma
CN101564464A (en) * 2009-06-01 2009-10-28 朱志真 Chinese medicament for adjusting organism immunity of tumor patients

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
许宗宽等.消癌利生抗肿瘤作用研究.《中国药学杂志》.1999,第34卷(第04期), *
许宗宽等.消癌利生治疗胃癌、贲门癌120例疗效观察.《河南肿瘤学杂志》.1995,第8卷(第03期), *

Also Published As

Publication number Publication date
CN102058854A (en) 2011-05-18

Similar Documents

Publication Publication Date Title
CN103721131B (en) A kind of Chinese medicine suppository and its preparation method treating women's chronic pelvic inflammatory disease
CN103861079A (en) Traditional Chinese medicine composition with effects of clearing heat, relieving pain and eliminating tumors
CN102225181B (en) Medicament for treating benign prostatic hyperplasia disease and preparation method thereof
CN104857435B (en) A kind of Traditional Chinese medicine compound composition with antitumor activity and its preparation method and application
CN1284599C (en) Medicine for treating tumor and its preparation process
CN103169737A (en) Composite of Antrodia camphorata entity and shell-broken ganoderma lucidum spore powder and application thereof in immune adjustment
CN101711848B (en) Chinese medicinal composition capable of adjunctively treating tumour
CN102188638A (en) Medicament for treating liver cancer
CN102579803B (en) Medicine for treating post-chemotherapy leucopenia and preparation method thereof
CN102058854B (en) Chinese medicine for treating malignant lymphoma
CN101293060B (en) Traditional Chinese medicine for treating cytology specification adenocarcinoma
CN101461894B (en) Medicament composition for treating female climacteric syndrome and delaying age
CN108813610A (en) A kind of saussurea involucrata composition and its application for improving immunity
CN104825922B (en) Chinese medicine composition with anti-colorectal carcinoma activity and its preparation method and application
CN101474388B (en) Improved prescription of Xianchan tablet medicament and preparation method thereof
CN103893700B (en) A kind of Chinese medicine composition treating breast carcinoma
CN100546611C (en) A kind of Chinese medicine preparation for the treatment of acquired immune deficiency syndrome (AIDS)
CN102293920B (en) Medicine composition for treating primary liver cancer and preparation method thereof
CN102008563B (en) Anticancer traditional Chinese medicine and preparation method thereof
CN104840716B (en) Traditional Chinese medicine compound composition with anti-breast cancer activity and its preparation method and application
CN107184912A (en) The positive disperse accumulations compound preparation of one breeding and its application
CN100546621C (en) A kind of new purposes of known drug
CN102805799A (en) Traditional Chinese medicine composition with antitumous effect
CN104042669A (en) Traditional Chinese medicine for treating liver cancer
CN100443093C (en) AIDS treating medicine

Legal Events

Date Code Title Description
PB01 Publication
C06 Publication
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
GR01 Patent grant
C14 Grant of patent or utility model